



UNITED STATES PATENT AND TRADEMARK OFFICE

1640205

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/823,253	04/12/2004	Jennifer Lynne Reed	10271-112-999	5470

7590 02/20/2008

MedImmune Inc.
One Medimmune Way
Gaithersburg, MD 20878

EXAMINER	
SKELDING, ZACHARY S	

ART UNIT	PAPER NUMBER
1644	

MAIL DATE	DELIVERY MODE
02/20/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

RECEIVED

FEB 21 2008

Initial: RA



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Serial No. : 10/823,253
Applicant : REED, JENNIFER LYNNE, et al
Filing Date : 04/12/2004
Date of Notice : 02/20/2008

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Notice of Allowance Mailed

This application has been accorded an Allowance Date and is being prepared for issuance. The application, however, is incomplete for the reasons below.

Applicant is given 1 month from the date of this Notice within which to correct the informalities indicated below. If the informality pertains to the abstract, specification (including claims) or drawings, the informality must be corrected with an amendment in compliance with 37 CFR 1.121 (or, if the application is a reissue application, 37 CFR 1.173). Such an amendment may be filed after payment of the issue fee if limited to correction of informalities noted herein. See Waiver of 37 CFR 1.312 for Documents Required by the Office of Patent Publication, 1280 Off. Gaz. Patent Office 918 (March 23, 2004). In addition, if the informality is not corrected until after payment of the issue fee, for purposes of 35 U.S.C. 154(b)(1)(iv), "all outstanding requirements" will be considered to have been satisfied when the informality has been corrected. A failure to reply will result in the application being ABANDONED. **This period for reply is NOT extendable under 37 CFR 1.136(a).**

See attachment.

*A copy of this notice **MUST** be returned with the reply. Please address response to
"Mail Stop Issue Fee, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450".*

/Bradley Harris/
Bradley Harris
Office of Data Management
Phone: 703-308-9250, ext. 141

Application No. 10/823,253

IDENTIFICATION OF APPLICATION DEFICIENCIES

- ☐ Applicant must provide legible text for the following item(s).
- ☐ Specification filed _____, page(s) _____.
 - ☐ Claims filed _____, claim(s) _____.
 - ☐ Oath/declaration filed _____.
 - ☐ Other: _____.
- ☒ Applicant must provide missing information on the following page(s) of the specification by amending the specification to add the missing text. No new matter may be added.
Page/line no(s). **Page 90, line 13 of the Specification, replace the attorney docket number with a U.S. Serial Number (see attached).**
- ☐ Applicant must provide an Abstract of the Disclosure.
- ☐ Applicant has submitted a "DECLARATION (37 CFR 1.63) FOR A UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)" (e.g., form PTO/SB/01A). The Application Data Sheet, however, is not present with the filed application. Applicant must submit an Application Data Sheet or file a new oath or declaration (e.g., PTO/SB/01) executed by the inventors and containing the information required in 37 CFR 1.63.
- ☐ Applicant must provide an executed declaration.
- ☐ Applicant must provide a declaration signed by inventor(s) _____.
- ☐ The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date may be required. See MPEP §§ 602.01 and 602.02. The oath or declaration is defective because:
- ☐ It does not identify the city and either state or foreign country of residence of each inventor. The residence information may be provided on either an application data sheet or a supplemental oath or declaration.
 - ☐ The oath or declaration for the patent application was filed prior to December 1, 1997, and applicant has not given a post office address anywhere in the application papers as required by 37 CFR 1.33(a), which was in effect at the time of filing of the oath or declaration. A statement over applicant's signature providing a complete post office address is required.
 - ☐ It does not identify the mailing address of each inventor. A mailing address is an address at which an inventor customarily receives his or her mail and may be either a home or business address. The mailing address should include the ZIP Code designation. The mailing address may be provided in an application data sheet or a supplemental oath or declaration. See 37 CFR 1.63(c) and 37 CFR 1.76.
- ☐ Per 37 CFR § 1.63(a)(2), applicant must provide at least one given name without abbreviation for inventor(s) _____.

5.2 THERAPIES USEFUL IN COMBINATION WITH IL-9 ANTIBODIES

[00232] The present invention also provides methods for preventing, managing, treating, and/or ameliorating diseases and disorders including, but not limited to, disorders characterized by aberrant expression and/or activity IL-9, disorders characterized by aberrant expression and/or activity of an IL-9R or one or more subunits thereof, inflammatory disorders, autoimmune disorders, proliferative disorders, or infections (preferably, respiratory infections) comprising administering to a subject in need thereof an effective amount of one or more antibodies that immunospecifically bind to an IL-9 polypeptide and one or more therapies (*e.g.*, prophylactic or therapeutic agents) other than antibodies that immunospecifically bind to an IL-9 polypeptide (*see* U.S. Provisional Appn. No. 60/477,801, filed June 10, 2003, entitled "Methods of Preventing or Treating Respiratory Conditions," U.S. Provisional Appn. No. 60/462,307, filed April 11, 2003, entitled "Methods of Preventing or Treating Respiratory Conditions," and a U.S. Provisional Application (identified by Attorney Docket No. 10271-113-999) filed concurrently herewith (April 12, 2004), entitled "Methods of Preventing or Treating Respiratory Conditions," which are all incorporated by reference herein in their entireties). The present invention also provides compositions comprising one or more antibodies that immunospecifically bind to an IL-9 polypeptide and one or more prophylactic or therapeutic agents other than antibodies that immunospecifically bind to an IL-9 peptide and methods of preventing, managing, treating, and/or ameliorating a disease or disorder utilizing said compositions. Therapeutic or prophylactic agents include, but are not limited to, small molecules, synthetic drugs, peptides, polypeptides, proteins, nucleic acids (*e.g.*, DNA and RNA nucleotides including, but not limited to, antisense nucleotide sequences, triple helices, RNAi, and nucleotide sequences encoding biologically active proteins, polypeptides or peptides) antibodies, synthetic or natural inorganic molecules, mimetic agents, and synthetic or natural organic molecules.

[00233] Any therapy (*e.g.*, prophylactic or therapeutic agents) which is known to be useful, or which has been used or is currently being used for the prevention, management, treatment, or amelioration of one or more symptoms associated with a disorder characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disorder or disease associated with aberrant expression and/or activity of an IL-9R or one or more subunits thereof, an inflammatory disorder, an autoimmune disorder, a proliferative disorder or an infection (preferably, a respiratory infection) can be used in combination with an antibody that immunospecifically binds to an IL-9 polypeptide in accordance with the invention described herein. See, *e.g.*, Gilman *et al.*, *Goodman and Gilman's: The*